DMK Pharmaceuticals Stock Price, News & Analysis (NASDAQ:DMK) $0.57 +0.03 (+5.58%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.50▼$0.5750-Day Range$0.48▼$0.7752-Week Range$0.45▼$21.70Volume125,040 shsAverage Volume122,174 shsMarket Capitalization$5.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media About DMK Pharmaceuticals Stock (NASDAQ:DMK)DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.Read More DMK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DMK Stock News HeadlinesDecember 1, 2023 | usatoday.comArizona attorney general sues pharmaceutical manufacturers for insulin price inflation schemeNovember 28, 2023 | finanznachrichten.deDMK Pharmaceuticals Corporation: DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI and Provides Corporate UpdateDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 28, 2023 | finance.yahoo.comDMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate UpdateNovember 25, 2023 | ca.finance.yahoo.comArcimoto, Inc. (FUV)November 24, 2023 | americanbankingnews.comDMK Pharmaceuticals (NASDAQ:DMK) Trading 2.1% Higher November 21, 2023 | morningstar.comDMK Pharmaceuticals CorpNovember 14, 2023 | finanznachrichten.deDMK Pharmaceuticals Corporation: DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 14, 2023 | sfgate.comDMK Pharmaceuticals: Q3 Earnings SnapshotNovember 14, 2023 | msn.comDMK Pharmaceuticals GAAP EPS of -$0.20November 14, 2023 | finance.yahoo.comDMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comDMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023October 21, 2023 | finanznachrichten.deDMK Pharmaceuticals Corporation: DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)October 20, 2023 | finance.yahoo.comDMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)October 20, 2023 | finanznachrichten.deDMK Pharmaceuticals Corporation: DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of GrowthOctober 19, 2023 | marketwatch.comDMK Pharmaceuticals Names Seth Cohen as Finance ChiefOctober 19, 2023 | msn.comDMK Pharmaceuticals appoints Seth Cohen as CFO, succeeding David MarguglioOctober 19, 2023 | finance.yahoo.comDMK Pharmaceuticals Restructures Executive Team to Support Next Phase of GrowthSeptember 28, 2023 | wsj.comDMK Pharmaceuticals Corp.September 28, 2023 | marketwatch.comDMK Pharmaceuticals Shares More Than Double on Canada Patent for OpioidSee More Headlines Receive DMK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DMK Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DMK CUSIPN/A CIK887247 Webwww.dmkpharmaceuticals.com Phone858-997-2400FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,480,000.00 Net Margins-630.85% Pretax Margin-600.29% Return on EquityN/A Return on Assets-251.02% Debt Debt-to-Equity RatioN/A Current Ratio0.58 Quick Ratio0.54 Sales & Book Value Annual Sales$4.76 million Price / Sales1.20 Cash FlowN/A Price / Cash FlowN/A Book Value($0.52) per share Price / Book-1.09Miscellaneous Outstanding Shares10,100,000Free Float9,506,000Market Cap$5.73 million OptionableNot Optionable Beta1.25 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. David J. Marguglio (Age 53)Co-Founder, President & COO Comp: $526.35kDr. Ebrahim Versi M.D. (Age 70)Ph.D., CEO & Chair of the Board Mr. Seth Abraham Cohen (Age 60)Chief Financial Officer Mr. John W. Dorbin Jr. (Age 52)General Counsel Corporate Secretary Ms. Jennifer C. SuskiSenior Director of MarketingMr. Eddie Wabern Glover (Age 73)Chief Executive Officer of US Compounding Inc Mr. Robert B. Rothermel (Age 79)Consultant Comp: $41.81kMore ExecutivesKey CompetitorsBright Minds BiosciencesNASDAQ:DRUGCyclerion TherapeuticsNASDAQ:CYCNEterna TherapeuticsNASDAQ:ERNAAgile TherapeuticsNASDAQ:AGRXVallon PharmaceuticalsNASDAQ:VLONView All Competitors DMK Stock Analysis - Frequently Asked Questions How have DMK shares performed in 2023? DMK Pharmaceuticals' stock was trading at $0.6655 on January 1st, 2023. Since then, DMK stock has decreased by 14.7% and is now trading at $0.5677. View the best growth stocks for 2023 here. When is DMK Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our DMK earnings forecast. How do I buy shares of DMK Pharmaceuticals? Shares of DMK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:DMK) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DMK Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.